supporting factors were the return-to-expansion of export goods and private final consumption expenditure. In addition, the relaxation of the COVID-19 restrictions resulting in the number of foreign tourist
the first time. The economics of scale has already improved and the synergetic effect between both companies will increase throughout 2019 particularly on the fixed cost side. EBITDA in Q1 2018 improved
the second half of the year. However, government expenditure was slightly decline as well as the contraction on agricultural and construction sector. The Thai economy in 2018 is expected to expand more
14,195.4 13,797.5 +2.9% 12,448.8 +10.8% [ Sales Revenue, USD $420.4 $394.0 +6.7% $364.9 +7.9% ] Cost of Sales 9,933.1 8,985.0 8,535.0 Gross margin, (%) 30.0% 34.9% 31.4% Selling&Administration 1,817.6
from the year 2017. This is because the government expenditure budget focused on the infrastructure and transportation, while the expenditure in information communication technology did not increased
-Y [2Q18 VS 1Q18] [2Q18 VS 2Q17] FX: THB/USD 31.575 31.529 34.172 Sales Revenue 3,643.3 3,440.2 +5.9% 3,663.5 -0.6% [ Sales Revenue, USD $115.4 $109.1 +5.8% $107.2 +7.6% ] Cost of Sales 2,628.9 2,551.4
(decreased) 2018 2017 Amount % Total revenues 820.40 815.31 5.09 0.62 Total expenses and finance cost 799.70 782.71 16.99 2.17 Share of profit from investments in associated companies 84.23 10.55 73..68 698.45
) Description For the year ending 31 December Year Increased (decreased) 2017 2016 Amount % Total revenues 815.31 791.94 23.37 2.95 Total expenses and finance cost 782.71 762.13 20.58 2.70 Share of profit from
comparison with the previous year, due to the delay approval process of budget expenditure of the government for the 2020 fiscal year. • Revenues from sales and beauty treatment services for the year 2019 were
, The Company’s strategies such as increasing more specialty cilinics, medical instruments and expanding into new market so as to drive a sustainable growth Cost of Hospital Operations The costs of